415 related articles for article (PubMed ID: 16097843)
1. Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
[TBL] [Abstract][Full Text] [Related]
4. Health economic burden of patients with restless legs syndrome in a German ambulatory setting.
Dodel R; Happe S; Peglau I; Mayer G; Wasem J; Reese JP; Giani G; Geraedts M; Trenkwalder C; Oertel WH; Stiasny-Kolster K
Pharmacoeconomics; 2010; 28(5):381-93. PubMed ID: 20297866
[TBL] [Abstract][Full Text] [Related]
5. Costs of illness in a Russian cohort of patients with Parkinson's disease.
Winter Y; von Campenhausen S; Popov G; Reese JP; Klotsche J; Bötzel K; Gusev E; Oertel WH; Dodel R; Guekht A
Pharmacoeconomics; 2009; 27(7):571-84. PubMed ID: 19663528
[TBL] [Abstract][Full Text] [Related]
6. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
7. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
8. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
Cubo E; Martínez Martin P; González M; Frades B;
Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
[TBL] [Abstract][Full Text] [Related]
9. Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis.
Martinez-Martín P; Rodriguez-Blazquez C; Paz S; Forjaz MJ; Frades-Payo B; Cubo E; de Pedro-Cuesta J; Lizán L;
PLoS One; 2015; 10(12):e0145310. PubMed ID: 26698860
[TBL] [Abstract][Full Text] [Related]
10. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
LePen C; Wait S; Moutard-Martin F; Dujardin M; Ziégler M
Pharmacoeconomics; 1999 Jul; 16(1):59-69. PubMed ID: 10539122
[TBL] [Abstract][Full Text] [Related]
11. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
12. [Cost of illness and health service patterns in Morbus Parkinson in Austria].
von Campenhausen S; Winter Y; Gasser J; Seppi K; Reese JP; Pfeiffer KP; Geiger-Gritsch S; Bötzel K; Siebert U; Oertel WH; Dodel R; Poewe W
Wien Klin Wochenschr; 2009; 121(17-18):574-82. PubMed ID: 19890747
[TBL] [Abstract][Full Text] [Related]
13. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach.
Dodel RC; Höffken H; Möller JC; Bornschein B; Klockgether T; Behr T; Oertel WH; Siebert U
Mov Disord; 2003 Oct; 18 Suppl 7():S52-62. PubMed ID: 14531047
[TBL] [Abstract][Full Text] [Related]
15. [Cost of illness in Parkinson disease. A retrospective 3-month analysis of direct costs].
Dodel RC; Singer M; Köhne-Volland R; Selzer R; Scholz W; Rathay B; Oertel WH
Nervenarzt; 1997 Dec; 68(12):978-84. PubMed ID: 9465341
[TBL] [Abstract][Full Text] [Related]
16. Cost of illness in patients with Gilles de la Tourette's syndrome.
Dodel I; Reese JP; Müller N; Münchau A; Balzer-Geldsetzer M; Wasem J; Oertel WH; Dodel R; Müller-Vahl K
J Neurol; 2010 Jul; 257(7):1055-61. PubMed ID: 20179960
[TBL] [Abstract][Full Text] [Related]
17. Cost of Parkinson's disease among Filipino patients seen at a public tertiary hospital in Metro Manila.
Prado M; Jamora RD
J Clin Neurosci; 2020 Apr; 74():41-46. PubMed ID: 31983646
[TBL] [Abstract][Full Text] [Related]
18. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
19. [Direct costs for Parkinson's treatment in private neurology practices in Berlin].
Ehret R; Balzer-Geldsetzer M; Reese JP; Dodel I; Becker E; Christopher A; Friedrich H; Kraemer S; Lüer W; Müngersdorf M; Puzich R; Rohr A; Schultes-Platzek I; Siefjediers V; Tiel-Wilck K; Oertel WH; Dodel R
Nervenarzt; 2009 Apr; 80(4):452-8. PubMed ID: 19252890
[TBL] [Abstract][Full Text] [Related]
20. [Atrial fibrillation in Germany: A prospective cost of illness study].
Spyra A; Daniel D; Thate-Waschke IM; Berghaus S; Willich S; Zeymer U; Rychlik R
Dtsch Med Wochenschr; 2015 Jul; 140(14):e142-8. PubMed ID: 26182263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
